Cossu Rocca

Introduction Nasopharyngeal carcinoma (NPC) presentation varies according to geographic area, with age-standardized incidence rates varying from 3.0 to 0.42 per 100.000 in Asia and Europe, respectively (1). NPC is a highly chemo-radiosensitive disease (2). However, up to 15% of patients develop local failure, and 15% to 30% distant metastasis. The lack of salvage treatment opportunities in these cases portends a poor prognosis (3, 4).

LONG-LASTING RESPONSES WITH CHEMOTHERAPY FOLLOWED BY T-CELL THERAPY IN RECURRENT OR METASTATIC EBV-RELATED NASOPHARYNGEAL CARCINOMA Simona Secondino1 , Paolo Pedrazzoli1, 2, 3* , Sabrina Basso4, 5 , Paolo Bossi6 , Alba Bianco4, 5, Ilaria Imarisio1, Anna Pagani1 , Marica De Cicco5, Stella Muscianisi4, 5 , Michela Casanova7 , Carlo Morosi8, Cristiana Bergamini9 , Marco Benazzo10, 11, Maria Cossu Rocca12 , Cesare Perotti13 , Fausto Baldanti10, 14 , Marco Zecca15 , Lisa F.

Original Articles: Genitourinary Aurilio, Gaetano MD, PhD*; Verri, Elena MD*; Frassoni, Samuele MSc†; Bagnardi, Vincenzo PhD†; Cossu Rocca, Maria MD*; Cullurà, Daniela MD*; Milani, Martina PharmD‡; Mascia, Roberta MD*; Curigliano, Giuseppe MD, PhD§; Orsi, Franco MD∥; Jereczek-Fossa, Barbara A.